Physician profile
Meredith B Young
NPI 1346502564
$1,200.15
in general payments reported to CMS, 2019-2025
21 companies · $171 in 2025
The $171 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.29 · 2020: $69.91 · 2021: $48.47 · 2022: $297 · 2023: $324 · 2024: $202 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $697.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $282.44 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $194.93 | 2019-2024 | Proclaim, Eterna, Freestyle Libre 3 |
| Abbvie INC. | $101.92 | 2020-2025 | |
| Pfizer INC. | $70.35 | 2019-2025 | |
| Astellas Pharma US INC | $69.87 | 2024-2025 | Veozah |
| Lucid Diagnostics INC. | $53.01 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.36 | 2021-2022 | |
| Lilly USA, LLC | $47.37 | 2023-2024 | Jardiance, Emgality |
| Azurity Pharmaceuticals, INC. | $40.77 | 2023-2024 | Horizant, Horizant |
| Ironshore Pharmaceuticals INC. | $37.76 | 2023 | Jornay Pm |
| Astrazeneca Pharmaceuticals LP | $35.05 | 2024-2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $31.22 | 2019-2023 | Shingrix |
| Medline Industries LP | $26.85 | 2022 | |
| Corium, LLC | $26.49 | 2023 | Azstarys |
| Allergan, INC. | $25.49 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $22.45 | 2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.23 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.93 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $16.37 | 2023 | Lipiflow System Activator (Disposable) |
| Noven Therapeutics, LLC | $13.67 | 2023 | Xelstrym |
| Medtronic, INC. | $12.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.